Zoetis (NYSE:ZTS) 2026 Conference Transcript

Summary of Zoetis 2026 Conference Call Company Overview - Company: Zoetis (NYSE: ZTS) - Date: March 17, 2026 - Speaker: Kristin Peck, CEO Key Points Industry and Company Guidance - 2026 Guidance: Zoetis is guiding for 3.5% organic constant currency growth after achieving 6% in 2025 [1] - Growth Drivers: The growth will be driven by a diverse portfolio, particularly in core therapeutic areas such as dermatology, parasiticides, and pain management [2][3] - Livestock Growth: Historically, livestock growth has been around 2%-4%, but Zoetis has seen mid- to high-single-digit growth over the past three years and expects to outperform the market in 2026 [3] Financial Metrics - Price and Volume Assumptions: The company expects 2%-3% growth from price increases and the remainder from volume for 2026 [5] - Vet Clinic Visits: Despite a decline in visits, spending at vet clinics grew by 6% in Q4 2025, indicating a strong human-animal bond and willingness to spend on pet care [10][11] Competitive Landscape - Market Competition: Increased competition in dermatology and parasiticides is expected, but Zoetis remains confident in its brand loyalty and customer satisfaction [57][58] - New Products: The company is focusing on long-acting pain products and expects to launch new therapies in oncology, cardiology, and renal health, which are anticipated to be high-value markets [19][20][21] Supply Chain and External Factors - Impact of Oil Prices: The ongoing conflict in Iran has minimal direct sales impact (less than 1% of total sales), but rising oil prices could affect shipping costs [7][9] - Weather Impact: Q1 2026 has seen adverse weather conditions affecting the parasiticide market, which typically performs better in Q2 and Q3 [55][56] Innovation and R&D - AI in Drug Discovery: Zoetis is leveraging AI for early drug discovery and molecule selection, utilizing unique datasets that include clinical trial data and genetic information [49][50][51] - Future Products: The company is optimistic about the potential of new products in renal health, which is projected to be a $3-$4 billion market, contingent on improved diagnostic rates [20][31] Market Trends - Protein Demand: The growing global population and middle-class expansion are driving protein demand, with poultry, fish, and pork being the fastest-growing sources [35][36] - Health and Wellness Trends: An aging population is increasing the focus on health and wellness, which is expected to support protein consumption trends [44] Strategic Changes - Field Team Restructuring: Zoetis has restructured its go-to-market teams to enhance reach and frequency, focusing on specialty products and chronic care [46][48] Long-Term Outlook - 2030 Vision: Zoetis aims to continue growing its core franchises while exploring new therapeutic areas, emphasizing the importance of portfolio diversity and innovation [60][61] Additional Insights - Customer Satisfaction: High customer satisfaction rates (80%-90%) for key products like Apoquel and Simparica indicate strong brand loyalty [14][58] - Veterinary Engagement: The company is investing in professional service vets to enhance scientific conversations and support the growth of specialty products [48] This summary encapsulates the key insights and strategic directions discussed during the Zoetis 2026 conference call, highlighting the company's growth prospects, competitive landscape, and innovation strategies.